Allogeneic HSCT for autoimmune diseases: A retrospective study from the EBMT ADWP, IEWP, and PDWP working parties: Frontiers in Immunology

R Greco, M Labopin, M Badoglio, P Veys, JMF Silva, M Abinun, F Gualandi, M Bornhauser, F Ciceri, R Saccardi, A Lankester, T Alexander, AR Gennery, P Bader, D Farge, JA Snowden

Research output: Contribution to journalArticlepeer-review

Abstract

Background: This retrospective study assessed the use and long-term outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with severe autoimmune diseases (ADs), reported to the European Society for Blood and Marrow Transplantation (EBMT) registry. Methods: Between 1997 and 2014, 128 patients received allogeneic HSCT for various hematological (n = 49) and non-hematological (n = 79) refractory ADs. The median age was 12.7 years (0.2-62.2). Donors were syngeneic for seven, matched related for 46, unrelated for 51, haploidentical for 15, and cord blood for nine patients. Results: The incidence of grades II-IV acute graft-vs.-host disease (GvHD) was 20.8% at 100 days. Cumulative incidence of chronic GvHD was 27.8% at 5-years. Non-relapse mortality (NRM) was 12.7% at 100-days. Overall survival (OS) and Progression-Free Survival (PFS) were 70.2 and 59.4% at 5-years, respectively. By multivariate analysis, age
Original languageEnglish
JournalFrontiers in Immunology
Volume10
DOIs
Publication statusPublished - 2019

Fingerprint Dive into the research topics of 'Allogeneic HSCT for autoimmune diseases: A retrospective study from the EBMT ADWP, IEWP, and PDWP working parties: Frontiers in Immunology'. Together they form a unique fingerprint.

Cite this